Osimertinib-resistant NSCLC cells can induce the activation of fibroblasts by transferring exosomes containing lnc-MZT2A-5:1, which is considered to be a novel target for NSCLC treatment 123. This evidence concerns the gene MZT2A and non-small cell lung carcinoma.